GlassScriptPhysician profile
Sara Conn
NPI 1225704471
$4,403.68
in general payments reported to CMS, 2019-2025
28 companies · $687 in 2025
The $687 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $1,127 · 2023: $1,302 · 2024: $641 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.80 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $657.83 | 2021-2025 | Farxiga, Breztri, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.63 | 2021-2024 | Jardiance |
| Amgen INC. | $569.87 | 2021-2025 | Repatha, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $373.19 | 2023-2025 | |
| Novo Nordisk INC | $264.00 | 2021-2025 | Ozempic, Wegovy |
| Edwards Lifesciences Corporation | $235.22 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Actelion Pharmaceuticals US, INC. | $218.46 | 2023-2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $207.90 | 2021-2023 | Emblem Mri S-Icd |
| E.R. Squibb & Sons, L.L.C. | $180.26 | 2022-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $147.64 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $134.72 | 2022-2025 | |
| Daiichi Sankyo INC. | $129.31 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $128.03 | 2022-2024 | Verquvo |
| Pfizer INC. | $120.30 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.60 | 2022-2023 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $58.86 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $53.06 | 2024-2025 | Cologuard Collection Kit |
| Scpharmaceuticals INC. | $29.73 | 2023 | |
| Phathom Pharmaceuticals, INC. | $24.27 | 2025 | Voquezna |
| Dexcom, INC. | $23.35 | 2025 | Dexcom G6 Transmitter |
| Itamar Medical INC | $22.37 | 2024 | Watchpatone |
| Philips North America LLC | $20.77 | 2022 | |
| Abbvie INC. | $19.39 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.25 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.85 | 2023 | Arcalyst |
| Chiesi USA, INC. | $14.95 | 2023 | Kengreal |
| Lexicon Pharmaceuticals, INC. | $14.12 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $13.75 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.